Physician profile
Liwei E Huang
NPI 1912174939
$7,742.07
in general payments reported to CMS, 2019-2025
33 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $261 · 2021: $473 · 2022: $918 · 2023: $1,661 · 2024: $1,404 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,815 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,815.22 |
| Education | $232.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,075.94 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $1,046.25 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $918.54 | 2019-2025 | Farxiga, Imfinzi, Lokelma |
| Travere Therapeutics, INC. | $415.61 | 2022-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $389.15 | 2020-2024 | Acthar |
| Akebia Therapeutics INC | $346.72 | 2019-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $313.94 | 2021-2025 | Velphoro, Velphoro |
| Mallinckrodt Enterprises LLC | $307.52 | 2019 | |
| Vifor Pharma, INC. | $267.04 | 2019-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $262.91 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $255.71 | 2022-2025 | |
| Horizon Therapeutics Plc | $215.33 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $208.30 | 2023-2025 | |
| Ardelyx, INC. | $170.60 | 2023-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.92 | 2023-2025 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $154.98 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Daiichi Sankyo INC. | $147.33 | 2019-2024 | Injectafer |
| Novo Nordisk INC | $119.25 | 2023-2024 | Rybelsus, Ozempic, Rivfloza |
| Opko Pharmaceuticals, LLC | $116.36 | 2019-2024 | Rayaldee |
| Teva Pharmaceuticals USA, INC. | $109.67 | 2021 | |
| Ani Pharmaceuticals, INC. | $107.69 | 2022-2025 | Purified Cortrophin Gel |
| Shield Therapeutics INC | $102.25 | 2024-2025 | |
| Glaxosmithkline, LLC. | $96.39 | 2025 | Benlysta, Shingrix |
| Calliditas Therapeutics US INC. | $74.22 | 2023-2025 | Tarpeyo |
| Lilly USA, LLC | $61.45 | 2023-2024 | Jardiance |
| Scpharmaceuticals INC. | $49.38 | 2025 | |
| Apellis Pharmaceuticals, INC. | $48.91 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.19 | 2025 | |
| Alexion Pharmaceuticals, INC. | $45.93 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $29.86 | 2022 | |
| Baxter Healthcare | $28.57 | 2019-2022 | |
| Genentech USA, INC. | $23.71 | 2025 | |
| Ascendis Pharma Endocrinology INC | $20.45 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liwei Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.